We know that the Black Swan Research Initiative is critically important, so we want to keep you up to date on our plans and progress. For many patients, their future care may depend on the outcome of our research, and we are often asked for answers before the research has even begun. Unfortunately, results are not immediate, but we do have an aggressive schedule, and we expect to have initial answers early next year about the role of MRD-zero--and why it's important to find the cure.

What We Are Doing Now

We have already completed our work on how to define and identify MRD-zero clinically. Now we are working on standardized testing for MRD-zero, and we are looking back over previous studies to glean new information about MRD-zero and responses to treatment that may point toward a cure.

Qe are incorporating new information from other studies into our BSRI program. One example is the recently completed study on smoldering myeloma from our colleagues in Spain. We are also looking at new drug combinations already in clinical trials as a guide for our own next steps to find the cure.

Within the next two months we will have two in-person meetings of our international BSRI team: a mini-summit in New York in October and a full BSRI team meeting at ASH in December. While we work together continuously via phone and email, these face-to-face meetings give us the opportunity to exchange ideas, challenge concepts, and drive the project forward.

We are finalizing contracts for partial funding for BSRI. This is essential for acquiring the most sophisticated analytical equipment needed for our research, and to support the teams of researchers.

Personal donations are still the mainstay of the work at the IMF and we are planning to include BSRI at our annual fund-raising gala in November.

What You Can Do Now

For some patients, waiting is not an option. What can you do now? The most important step you can take for yourselves and to help your fellow patients is to take part in clinical trials. More than 1,300 trials are listed on Not all are still recruiting patients, some are for a specific subset of conditions, but that's a lot of patients needed from a relatively rare cancer. And of course, we hope you'll be available to take part as soon as our clinical trials begin.

Also, we hope you will please consider donating to the Black Swan Research Initiative. With your help, we will soon bridge the gap from long-term remission to cure.

Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.